Xiao Wang, MD
he/him/his
Instructor of Medicine (Medical Oncology & Hematology)About
Research
Publications
2026
A Taxonomy for Assessing Real-World Targeted Cancer Therapy Options in the Context of Broad Genomic Profiling.
Wang X, Long J, Rothen J, Huang S, Soulos P, Goldberg S, Robinson T, Ma S, Mamtani R, Presley C, Wang S, Kunst N, Gross C, Dinan M. A Taxonomy for Assessing Real-World Targeted Cancer Therapy Options in the Context of Broad Genomic Profiling. Journal Of The National Comprehensive Cancer Network 2026, 24 PMID: 41698347, DOI: 10.6004/jnccn.2025.7131.Peer-Reviewed Original ResearchThis study introduces Y-MATRIX, a taxonomy classifying genomic profiling results by clinical actionability, showing increased actionable findings in advanced lung cancer from 2017 to 2023.
2025
Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer
Nassar A, Farhat E, Abushukair H, Alchoueriy M, Salem S, Machaalani M, Adib E, Henske E, Babu P, Choueiri T, Rakaee M, Busund L, Takabe Y, Lau S, Rall K, Naqash A, Jansen C, Wang X, Challa P, Tarantino P, Partridge A, Tolaney S, Kwiatkowski D, Winer E. Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer. Journal Of The National Cancer Institute 2025, djaf344. PMID: 41418409, DOI: 10.1093/jnci/djaf344.Peer-Reviewed Original ResearchTime to next treatmentT-DXdOverall survivalImmune correlatesBreast cancerAssociated with significantly worse OSHER2-expressing breast cancerPrognostic biomarkerMultivariate Cox proportional hazards modelBiomarker-driven strategiesHER2-0 tumoursHER2-low diseaseImmune-desert phenotypesSequential tumor biopsiesInflamed tumor microenvironmentAdvanced breast cancerDana-Farber Cancer InstituteCox proportional hazards modelsProportional hazards modelHER2-lowTrastuzumab deruxtecanHER2 immunohistochemistryERBB2 amplificationTumor biopsiesTumor microenvironmentMolecular Biomarker Testing Patterns and Turnaround Time in US Patients With Advanced Non-Small Cell Lung Cancer.
Wang X, Lee D, Yang S, Li Y, Soulos P, Gross C, Wang S, Chiang A. Molecular Biomarker Testing Patterns and Turnaround Time in US Patients With Advanced Non-Small Cell Lung Cancer. Journal Of The National Comprehensive Cancer Network 2025, 23: 461-467. PMID: 41072474, DOI: 10.6004/jnccn.2025.7063.Peer-Reviewed Original ResearchAdvanced non-small cell lung cancerLong test turnaround timesNon-small cell lung cancerCell lung cancerRetrospective cohort studyTest turnaround timeNext-generation sequencingTargeted therapyClinical outcomesAssociated with worse median progression-free survivalLung cancerUS patientsElectronic health record-derivedMedian progression-free survivalRetrospective cohort study of patientsNontarget treatmentCohort study of patientsProgression-free survivalTargetable genomic alterationsFirst-line treatmentHistory of smokingStudy of patientsNGS useEGFR testingNontargeted therapiesAdoption of Broad Genomic Profiling in Patients With Cancer
Wang X, Rothen J, Huang S, Long J, Soulos P, Goldberg S, Mamtani R, Presley C, Kunst N, Ma S, Wang S, Gross C, Dinan M. Adoption of Broad Genomic Profiling in Patients With Cancer. JAMA Oncology 2025, 11: 666-668. PMID: 40244595, PMCID: PMC12006912, DOI: 10.1001/jamaoncol.2025.0499.Peer-Reviewed Original Research
2024
Antibiotic practice and stewardship in the management of neutropenic fever: a survey of US institutions
Wang X, Arya S, Patel S, Saw S, Decena M, Hirsh R, Pegues D, Ziegler M. Antibiotic practice and stewardship in the management of neutropenic fever: a survey of US institutions. Infection Control And Hospital Epidemiology 2024, 45: 1168-1175. PMID: 39087709, PMCID: PMC11611503, DOI: 10.1017/ice.2024.103.Peer-Reviewed Original ResearchSociety for Healthcare EpidemiologyNeutrophil recoverySociety for Healthcare Epidemiology of America Research NetworkFever managementHealthcare institutionsManagement of neutropenic feverFever management practicesFirst-line therapyBone marrow transplantationFirst-line treatmentAntipseudomonal antibioticsNeutropenic feverAntimicrobial prophylaxisMarrow transplantationTreatment courseAntibiotic practicesElectronic surveySupportive careDe-EscalationResearch NetworkInstitutional guidelinesSurvey studyRobust evidenceProphylaxisResponding institutionsBig Decisions on Small Cell Lung Cancer: A Focus on Clinical Care Updates and Patient Perspectives.
Wang X, Chiang A. Big Decisions on Small Cell Lung Cancer: A Focus on Clinical Care Updates and Patient Perspectives. American Society Of Clinical Oncology Educational Book 2024, 44: e432520. PMID: 38830134, DOI: 10.1200/edbk_432520.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSmall cell lung cancerCell lung cancerLung cancerSystemic therapyHigh-grade neuroendocrine carcinomaAssociated with tobacco useIntracranial radiotherapySCLC treatmentChemosensitive diseaseNeuroendocrine carcinomaTargeted therapyPatientsCancerTherapyTobacco usePsychosocial burdenDiseasePatient perspectiveRadiotherapyImmunotherapyCarcinomaRelapseThoracicLungClinic
2023
Clinical Outcomes Associated With Pembrolizumab Monotherapy Among Adults With Diffuse Malignant Peritoneal Mesothelioma
Marmarelis M, Wang X, Roshkovan L, Grady C, Miura J, Ginsberg M, Ciunci C, Egger J, Walker S, Cercek A, Foote M, Litzky L, Nash G, Haas A, Karakousis G, Cengel K, Katz S, Zauderer M, Langer C, Offin M. Clinical Outcomes Associated With Pembrolizumab Monotherapy Among Adults With Diffuse Malignant Peritoneal Mesothelioma. JAMA Network Open 2023, 6: e232526. PMID: 36897589, PMCID: PMC10942662, DOI: 10.1001/jamanetworkopen.2023.2526.Peer-Reviewed Original ResearchConceptsDiffuse malignant peritoneal mesotheliomaMedian progression-free survivalProgression-free survivalMalignant peritoneal mesotheliomaMedian OSPembrolizumab monotherapyEpithelioid histologyPartial responsePD-L1Nonepithelioid histologyOverall survivalPeritoneal mesotheliomaPositive tumor PD-L1 expressionTertiary care academic cancer centerCohort studyAssociation of disease characteristicsInitiation of pembrolizumab monotherapyTumor PD-L1 expressionProgrammed death-ligand 1Dual-center cohort studyPD-L1 positivityMedian overall survivalPartial response ratePD-L1 expressionPD-L1 statusA Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non–Small Cell Lung Cancer
Iams W, Balbach M, Phillips S, Sacher A, Bestvina C, Velcheti V, Wang X, Marmarelis M, Sethakorn N, Leal T, Sackstein P, Kim C, Robinson M, Mehta K, Hsu R, Nieva J, Patil T, Camidge D. A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non–Small Cell Lung Cancer. Clinical Lung Cancer 2023, 24: 228-234. PMID: 36841727, PMCID: PMC10234144, DOI: 10.1016/j.cllc.2023.01.009.Peer-Reviewed Original ResearchConceptsMutant non-small cell lung cancerNon-small cell lung cancerMulticenter retrospective chart reviewCell lung cancerClinical outcomesFood and Drug AdministrationStage IVMedian OSPD-(L)1Second-lineOverall survivalSystemic therapySTK11 mutationsKRAS G12C mutated non-small cell lung cancerLung cancerPatient populationFDA-approved targeted therapyPD-(L)1 inhibitor monotherapyRetrospective chart review of patientsSecond-line systemic therapyFirst-line systemic therapyChart review of patientsReview of clinical outcomesDocetaxel-containing regimensDocetaxel-treated patients
2022
A single-center retrospective cohort study of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma
Wang X, Katz S, Miura J, Karakousis G, Roshkovan L, Walker S, McNulty S, Ciunci C, Cengel K, Langer C, Marmarelis M. A single-center retrospective cohort study of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma. PLOS ONE 2022, 17: e0275187. PMID: 36174024, PMCID: PMC9521908, DOI: 10.1371/journal.pone.0275187.Peer-Reviewed Original ResearchConceptsDiffuse malignant peritoneal mesotheliomaMedian overall survivalHyperthermic intraperitoneal chemotherapySingle-center retrospective cohort studyMalignant peritoneal mesotheliomaNeoadjuvant chemotherapyCytoreductive surgeryRetrospective cohort studySystemic chemotherapyAdjuvant chemotherapyNeoadjuvant patientsOverall survivalPeritoneal mesotheliomaAssociated with worse median overall survivalDMPM patientsCohort studyEstimated median overall survivalHazard ratioAssociated with worse outcomesPerioperative systemic chemotherapyOutcomes of patientsKaplan-Meier curvesCox proportional hazards modelsPre-operative periodMalignant mesothelioma casesSevere aplastic anaemia after serial vaccinations for SARS‐CoV‐2, pneumococcus and seasonal influenza
Wang X, Laczko D, Caponetti G, Rabatin S, Babushok D. Severe aplastic anaemia after serial vaccinations for SARS‐CoV‐2, pneumococcus and seasonal influenza. EJHaem 2022, 3: 983-988. PMID: 35941884, PMCID: PMC9348402, DOI: 10.1002/jha2.443.Peer-Reviewed Case Reports and Technical NotesSevere aplastic anemiaAplastic anemiaDevelopment of severe aplastic anemiaSARS-CoV-2MRNA SARS-CoV-2 vaccineSARS-CoV-2 vaccinesProgressive pancytopeniaInfluenza vaccineSeasonal influenzaProgressive symptomsRespiratory syndrome coronavirus 2Vaccine exposureSyndrome coronavirus 2Vaccine sequenceVaccineInfluenzaAnemiaVaccination effortsCoronavirus 2Coronavirus diseasePancytopeniaPneumococcal
Clinical Trials
Current Trials
A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-Line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction (GEJ) Cancer (Destiny-Gastric05)
IRB ID2000040953RoleSub InvestigatorPrimary Completion Date05/01/2027Recruiting ParticipantsA Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms
IRB ID2000041573RoleSub InvestigatorPrimary Completion Date12/31/2027Recruiting ParticipantsA Phase 1/2 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants With Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors
IRB ID2000041512RoleSub InvestigatorPrimary Completion Date08/01/2027Recruiting ParticipantsA Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-26808 Alone or in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
IRB ID2000036028RoleSub InvestigatorPrimary Completion Date08/01/2026Recruiting ParticipantsA Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination With Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in Participants Whose Tumors Are HER2-negative, Claudin (CLDN) 18.2-positive and Programmed Death-ligand 1 (PD-L1)-Positive
IRB ID2000039866RoleSub InvestigatorPrimary Completion Date03/01/2028Recruiting Participants
Academic Achievements & Community Involvement
Clinical Care
Overview
Clinical Specialties
Medical Oncology; Gastrointestinal Oncology
News
News
Get In Touch
Contacts
Appointment Number
Mailing Address
Yale School of Medicine
333 Cedar Street
New Haven, Connecticut 06510
United States
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
Events
May 202621Thursday
Everyone Jill Lacy, MD - Xiao Wang, MD - Michael Cecchini, MD - John Kunstman, MD, MHS, FACSZoom link will be sent when you register